J Rheumatol
-
To assess the quality of reporting in Cochrane musculoskeletal systematic reviews (excluding back and injury reviews). ⋯ Our study found that the reporting quality of Cochrane musculoskeletal systematic reviews was generally good, although there was room for improvement. For example, it might be feasible to develop specific guidelines for reporting protocols. Certainly more work is needed in reporting search results, documentation of the flow of studies, identification of the type of studies, and summarization of the key findings.
-
We describe a series of cases to evaluate the effect of intraarticular infliximab in patients with ankylosing spondylitis (AS) with treatment-resistant arthritis, and to consider whether longterm treatment with intravenous infliximab could be avoided in these patients. ⋯ We observed a beneficial effect of IA infliximab in refractory arthritis in patients with AS. This procedure could be considered an effective and safe treatment for therapy of refractory monoarthritis in AS and an alternative for parenteral TNF-blocking therapy.
-
To revisit our previous evidence-based recommendations on the appropriate prescription of nonsteroidal antiinflammatory drugs (NSAID) with particular emphasis on cyclooxygenase-2 selective inhibitors (coxibs). ⋯ Coxibs continue to be an option in the treatment armamentarium. Given the evolving cardiovascular information, physicians and patients should weigh the benefits and risks of NSAID/coxib treatment. This concern emphasizes the need to routinely reassess patients' risks. These recommendations, which were formulated according to the Appraisal of Guidelines for Research and Evaluation, are intended to be used as guidelines to supplement, but not replace, the physician's judgment in clinical decision-making.